Clinical Trial Update: CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS [Phase 1]

View source ↗

Summary

This Clinical Trial Update reports that a Phase 1 study of CYC065 in combination with Venetoclax for relapsed or refractory acute myeloid leukemia or myelodyspl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• CYC065 (CYC065)
• Venetoclax (venetoclax)

Snippet

Sponsor: Cyclacel Pharmaceuticals, Inc. | Conditions: AML, MDS | Phase 1 | Status: COMPLETED